CVE:VM Voyageur Pharmaceuticals (VM) Stock Price, News & Analysis C$0.26 -0.01 (-1.89%) As of 07/11/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Voyageur Pharmaceuticals Stock (CVE:VM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VM alerts:Sign Up Key Stats Today's RangeC$0.25▼C$0.2650-Day RangeC$0.16▼C$0.3452-Week RangeC$0.04▼C$0.36Volume89,000 shsAverage Volume198,655 shsMarket CapitalizationC$39.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in the acquiring, exploring, and developing raw materials for pharmaceutical products, primarily in the province of British Columbia, Canada, and the state of Utah. The company develops barium and iodine-based APIs. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. was founded in 2017 and is headquartered in Calgary, Canada. Read More Receive VM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyageur Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VM Stock News HeadlinesVoyageur Pharmaceuticals Ltd. (CVE:VM) Director Eugene Leonard Fritzel Acquires 32,250 SharesJuly 1, 2025 | insidertrades.comVoyageur Pharmaceuticals (CVE:VM) Trading Down 11.5% - Here's WhyJuly 7, 2025 | americanbankingnews.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.July 12 at 2:00 AM | American Alternative (Ad)Voyageur Pharmaceuticals (CVE:VM) Shares Down 11.5% - Should You Sell?July 7, 2025 | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Down 11.5% - Time to Sell?July 7, 2025 | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Trading Down 11.5% - Time to Sell?July 7, 2025 | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Down 11.5% - Here's WhyJuly 7, 2025 | americanbankingnews.comVoyageur Pharmaceuticals (CVE:VM) Stock Price Down 11.5% - Should You Sell?July 7, 2025 | americanbankingnews.comSee More Headlines VM Stock Analysis - Frequently Asked Questions How have VM shares performed this year? Voyageur Pharmaceuticals' stock was trading at C$0.09 at the beginning of the year. Since then, VM shares have increased by 205.9% and is now trading at C$0.26. How do I buy shares of Voyageur Pharmaceuticals? Shares of VM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Voyageur Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Voyageur Pharmaceuticals investors own include GFG Resources (GFG), Pine Cliff Energy (PNE), Tamarack Valley Energy (TVE), Caladrius Biosciences (CLBS), Capstone Copper (CS), Calibre Mining (CXB) and Mawson Gold (MAW). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:VM CIKN/A Webwww.voyageurminerals.ca Phone587-779-6166FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$1.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-117.77% Return on Assets-30.77% Debt Debt-to-Equity Ratio4.23 Current Ratio0.10 Quick Ratio0.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.01 per share Price / Cash Flow35.00 Book ValueC$0.01 per share Price / Book38.37Miscellaneous Outstanding Shares151,517,550Free FloatN/AMarket CapC$39.39 million OptionableNot Optionable Beta0.32 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (CVE:VM) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyageur Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyageur Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.